(Q39872545)

15 September 2017

title

K-RAS mutation in the screening, prognosis and treatment of cancer (English)

1 reference

15 September 2017

Barbara L Parsons

1

0 references

author name string

Fanxue Meng

series ordinal

2

1 reference

15 September 2017

publication date

1 December 2009

1 reference

15 September 2017

published in

Biomarkers in Medicine

1 reference

15 September 2017

volume

3

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

757-769

1 reference

Differential functions of Ras for malignant phenotypic conversion

15 September 2017

cites work

1 reference

EGFR antagonists in cancer treatment

21 January 2018

1 reference

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation.

21 January 2018

1 reference

K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.

21 January 2018

1 reference

Detection of a K-ras mutation in urine of patients with colorectal cancer

21 January 2018

1 reference

Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients

21 January 2018

1 reference

Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy

21 January 2018

1 reference

Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?

21 January 2018

1 reference

Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe

21 January 2018

1 reference

K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking

21 January 2018

1 reference

Transrenal DNA as a diagnostic tool: important technical notes.

21 January 2018

1 reference

Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer

21 January 2018

1 reference

K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers

21 January 2018

1 reference

Detection of K-ras and p53 mutations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis

21 January 2018

1 reference

Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening

21 January 2018

1 reference

Noninvasive testing for colorectal cancer: a review

21 January 2018

1 reference

Common gene polymorphisms, cancer progression and prognosis

21 January 2018

1 reference

Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer

21 January 2018

1 reference

Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test

21 January 2018

1 reference

DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests.

21 January 2018

1 reference

A novel high-specificity approach for colorectal neoplasia: Detection of K-ras2 oncogene mutation in normal mucosa.

21 January 2018

1 reference

Serum tumor markers and molecular biological diagnosis in pancreatic cancer

21 January 2018

1 reference

Stool screening for colorectal cancer: molecular approaches

21 January 2018

1 reference

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer

21 January 2018

1 reference

Fast simultaneous detection of K-RAS mutations in colorectal cancer

21 January 2018

1 reference

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

Origin and prognostic value of circulating KRAS mutations in lung cancer patients

21 January 2018

1 reference

Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

21 January 2018

1 reference

Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.

21 January 2018

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study

21 January 2018

1 reference

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

21 January 2018

1 reference

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

The marriage of growth factor inhibitors and chemotherapy: bliss or bust?

21 January 2018

1 reference

Treatment in advanced colorectal cancer: what, when and how?

21 January 2018

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

Development of farnesyl transferase inhibitors: a review

21 January 2018

1 reference

Targeting the RAS signaling pathway in malignant hematologic diseases

21 January 2018

1 reference

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras

21 January 2018

1 reference

Oligoclonality in bladder cancer: the implication for molecular therapies

21 January 2018

1 reference

Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression?

21 January 2018

1 reference

Many different tumor types have polyclonal tumor origin: evidence and implications.

21 January 2018

1 reference

Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients

21 January 2018

1 reference

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping

21 January 2018

1 reference

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

21 January 2018

1 reference

KRAS mutation testing in colorectal cancer

21 January 2018

1 reference

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

21 January 2018

1 reference

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

21 January 2018

1 reference

Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine

21 January 2018

1 reference

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens

21 January 2018

1 reference

Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing

21 January 2018

1 reference

Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis.

21 January 2018

1 reference

A novel mutant allele specific amplification and electrochemiluminescence method for the detection of point mutation in clinical samples

21 January 2018

1 reference

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

TP53andKRAS2Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study

21 January 2018

1 reference

Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.09.95

1 reference

15 September 2017

1 reference